Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
50.53
+0.93 (1.87%)
Oct 19, 2026, 1:44 PM EDT - Market open
Travere Therapeutics Revenue
Travere Therapeutics had revenue of $169.58M in the quarter ending June 30, 2026, with 48.17% growth. This brings the company's total for the last twelve months to $591.33M, up 77.12% year-over-year. In the year 2025, Travere Therapeutics had annual revenue of $490.73M with 110.45% growth. That makes Travere Therapeutics the 10,279th largest company in the world by revenue and 2,179th in the United States.
Revenue (ttm)
$591.33M
Revenue Growth
+77.12%
P/S Ratio
7.91
Revenue / Employee
$1,189,799
Employees
497
Market Cap
4.76B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 490.73M | 257.55M | 110.45% |
| Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
| Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
| Dec 31, 2022 | 109.46M | -118.03M | -51.88% |
| Dec 31, 2021 | 227.49M | 29.17M | 14.71% |
| Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
| Dec 31, 2019 | 175.34M | 11.09M | 6.75% |
| Dec 31, 2018 | 164.25M | 9.31M | 6.01% |
| Dec 31, 2017 | 154.94M | 21.35M | 15.98% |
| Dec 31, 2016 | 133.59M | 33.70M | 33.74% |
| Dec 31, 2015 | 99.89M | 71.69M | 254.19% |
| Dec 31, 2014 | 28.20M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.01B |
| Mirum Pharmaceuticals | 618.07M |
| CRISPR Therapeutics AG | 13.39M |
| CG Oncology | 6.23M |
| Dianthus Therapeutics | 1.90M |
TVTX News
- 6 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Travere Therapeutics announces FILSPARI data presentations at ASN Kidney Week - TheFly
- 17 days ago - Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 - Business Wire
- 25 days ago - Travere Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 25 days ago - Travere Therapeutics price target raised to $89 from $75 at Guggenheim - TheFly
- 26 days ago - Travere Therapeutics receives notice of allowance for FILSPARI patent - TheFly
- 26 days ago - Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis - Business Wire
- 27 days ago - Travere Therapeutics CEO Dube to step down - TheFly